We get the latest from the Munich Security Conference, where U.S. Secretary of State Marco Rubio delivered a speech before ...

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.

Q4 2025 earnings call highlights: revenue, cost cuts, cash outlook, FDA flu setback, and 2026 growth guidance—read key insights now.

With sales of Immunocore’s melanoma medicine steadily ticking up and an expanded label likely down the line, CEO Bahija Jallal, Ph.D., is mixing caution with ambition as she adjusts to working without ...

Moderna’s mRNA influenza vaccine faces US regulatory delays after a refusal-to-file letter from top FDA official Dr Vinay Prasad.

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

Moderna beat fourth-quarter sales expectations and forecast growth for 2026, but an FDA refusal on its flu vaccine raises new ...